Metonitazene
Appearance
File:Metonitazene.png | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H26N4O3 |
Molar mass | 382.464 g·mol−1 |
3D model (JSmol) | |
| |
|
Metonitazene is an analgesic drug related to etonitazene, which was first reported in 1957,[1] and has been shown to have approximately 100 times the potency of morphine by central routes of administration,[2] but if used orally it has been shown to have approximately 10 times the potency of morphine.[3]
Its effects are similar to other opioids like fentanyl and heroin, including analgesia, euphoria, sleepiness[3]. Adverse effects include vomiting, and respiratory depression that can potentially be fatal. Because of high dependency potential and dangerous adverse effects it has never been introduced in pharmacotherapy.
See also
References
- ^ Hunger A, Kebrle J, Rossi A, Hoffmann K (October 1957). "[Synthesis of analgesically active benzimidazole derivatives with basic substitutions]". Experientia. 13 (10): 400–1. doi:10.1007/bf02161116. PMID 13473817.
- ^ Hunger VA, Kebrle J, Rossi A, Hoffmann K (1960). "Benzimidazol-Derivate und verwandte Heterocyclen III. Synthese von 1-Aminoalkyl-2-nenzyl-nitro-benzimidazolen". Helvetica Chimica Acta. 43 (4): 1032–1046. doi:10.1002/hlca.19600430412.
- ^ a b Bromig G (October 1958). "[New powerful analgetics and their clinical testing]". Klinische Wochenschrift. 36 (20): 960–3. doi:10.1007/bf01486702. PMID 13612082.